Eventide Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Eventide Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.6M	Hold	437,130	–	–	0.44%	76
2026 Q1	$32.5M	Buy	437,130 +75,000	+21%	+$5.44M	0.54%	64
2025 Q4	$27.7M	Sell	362,130 -222,166	-38%	-$14.6M	0.43%	84
2025 Q3	$30.3M	Buy	584,296 +200,065	+52%	+$9.76M	0.5%	76
2025 Q2	$16.6M	Sell	384,231 -147,961	-28%	-$5.38M	0.29%	103
2025 Q1	$18.4M	Hold	532,192	–	–	0.37%	89
2024 Q4	$14.6M	Sell	532,192 -184,735	-26%	-$4.77M	0.27%	115
2024 Q3	$18.3M	Hold	716,927	–	–	0.31%	93
2024 Q2	$18.2M	Hold	716,927	–	–	0.31%	95
2024 Q1	$22.2M	Hold	716,927	–	–	0.35%	83
2023 Q4	$28.9M	Hold	716,927	–	–	0.47%	63
2023 Q3	$18.9M	Sell	716,927 -224,249	-24%	-$6.36M	0.34%	87
2023 Q2	$16.2M	Hold	941,176	–	–	0.27%	98
2023 Q1	$15.6M	Buy	+941,176	New	+$11M	0.29%	96
2021 Q3	–	Sell	-712,197	Closed	-$43.4M	–	154
2021 Q2	$43.4M	Hold	712,197	–	–	0.58%	56
2021 Q1	$43.9M	Buy	+712,197	New	+$46.6M	0.65%	59

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Eventide Asset Management's BBIO Position: Q2 2026 in Review

Eventide Asset Management held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 437,130 shares worth $32.6M. The position accounts for 0.44% of the portfolio, ranked #76.

Eventide Asset Management first reported a position in BBIO in Q1 2021 and has held it in 16 quarters since. The position peaked at $43.9M in Q1 2021. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Eventide Asset Management held 437,130 shares of BridgeBio Pharma worth $32.6M as of Q2 2026.
Eventide Asset Management left its BridgeBio Pharma share count unchanged in Q2 2026.
BridgeBio Pharma made up 0.44% of Eventide Asset Management's portfolio in Q2 2026, its #76 holding.
Eventide Asset Management first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 16 quarters since.
Eventide Asset Management's BridgeBio Pharma position peaked at $43.9M in Q1 2021.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.